PDL BioPharma ( PDLI), announced Tuesday the appointment of Andrew Guggenhime as senior vice president and chief financial officer, effective April 3. Guggenhime will report directly to Chief Executive Mark McDade, and will be responsible for all financial and information technology operations of the company. Guggenhime will join PDL BioPharma from Neoforma, where he had been finance chief since October 2000. "Andrew has the commercial, management and financial experience that PDL BioPharma requires in the CFO role as we focus on growth and solidify our position as a commercial biopharmaceutical company," said McDade. "We are delighted that he will join the company during an exciting time, as we create value from our diverse stream of product and royalty revenues, and advance our robust pipeline of six acute care focused products."